Sarepta Stock Drops Following Second Patient Death in Gene Therapy Trial
TL;DR Summary
Sarepta Therapeutics' stock plummeted nearly 50% to a nine-year low after a second patient treated with its Duchenne muscular dystrophy drug, Elevidys, died of acute liver failure, prompting the company to suspend shipments and review safety protocols.
Topics:business#acute-liver-failure#business#duchenne-muscular-dystrophy#elevidys#sarepta-therapeutics#stock-plunge
- Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug Investopedia
- Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy Barron's
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Sarepta Therapeutics
- Sarepta and Roche halt DMD gene therapy’s use after second death Yahoo Finance
- Sarepta Reports Second Death of Patient Using Its Gene Therapy Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
17
Time Saved
1 min
vs 2 min read
Condensed
89%
323 → 37 words
Want the full story? Read the original article
Read on Investopedia